Anthracycline-Sparing Strategies Help Refine HER2+ Breast Cancer Management
Paolo Tarantino, MD, discusses the growing emphasis on anthracycline-sparing approaches for the treatment of HER2-positive breast cancer.
Related Articles
Biomarker Research Aims to Overcome Treatment Challenges in Squamous Cell Carcinoma of the Lung
Fawzi F Abu Rous, MD, discusses ongoing efforts to address unmet needs in the management of squamous cell carcinoma of the lung.
ADCs Are Poised to Transform the Metastatic TNBC Treatment Arsenal
Nerea Lopetegui-Lia, MD, discusses ongoing trials investigating ADCs that are shaking up the metastatic triple-negative breast cancer setting.
Cyclin E1 Positivity May Enhance Patient Selection for Azenosertib in Platinum-Resistant Ovarian Cancer
Fiona Simpkins, MD, discusses the use of cyclin E1 positivity as a biomarker of azenosertib response in platinum-resistant ovarian cancer.
Personalized Therapy, Surgical Staging, and Expanded Screening Guidelines Drive Progress in NSCLC
Isabel Preeshagul, DO, MBS, discusses the need for a nuanced approach when selecting between targeted therapies in ALK- and EGFR-altered NSCLC.
Dr Monk on the FDA Approval of Avutometinib and Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.
Talazoparib/Enzalutamide Combo, Radioligand Therapy Expand Options in mCRPC
Marc R. Matrana, MD, discusses the evolving frontline treatment landscape for advanced metastatic prostate cancer.
Targeted Therapies Both Refine and Raise Questions About CRPC Treatment Decision-Making
Evan Y. Yu, MD, discusses PARP inhibitor treatment selection and sequencing for patients with metastatic castration-resistant prostate cancer.
Investigational and Established Biomarkers Guide Ongoing CRPC Therapy Developments
Evan Y. Yu, MD, discusses future directions for biomarker research and targeted therapy development for patients with castration-resistant prostate cancer.
FDA Receives sBLA for Nogapendekin Alfa Inbakicept in Papillary NMIBC
A sBLA for nogapendekin alfa inbakicept in BCG-unresponsive non–muscle-invasive bladder cancer with papillary disease was submitted to the FDA.
An EBMT Machine Learning Model Aids With Transplant Risk Stratification in Myelofibrosis
Juan Carlos Hernández-Boluda, MD, PhD, discusses the development of an EBMT machine learning model for predicting allo-HCT risk in myelofibrosis.